2/19
07:34 am
ganx
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/19
07:00 am
ganx
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
1/7
07:00 am
ganx
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Medium
Report
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
1/6
07:00 am
ganx
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
High
Report
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
12/19
03:03 pm
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.
12/19
08:04 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
12/18
04:05 pm
ganx
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
High
Report
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
12/18
07:32 am
ganx
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease [Yahoo! Finance]
High
Report
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease [Yahoo! Finance]
12/18
07:00 am
ganx
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
High
Report
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
12/11
04:18 pm
ganx
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/5
04:20 pm
ganx
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
07:20 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/29
01:34 am
ganx
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]
Medium
Report
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]